Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids and acellular pertussis adsorbed
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria and tetanus toxoids and acellular pertussis adsorbed is a combination vaccine used for active immunization against three serious bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough). The vaccine contains inactivated toxins (toxoids) from *Corynebacterium diphtheriae* (diphtheria) and *Clostridium tetani* (tetanus), as well as purified antigens from *Bordetella pertussis*. It works by stimulating the immune system to produce antibodies against these pathogens without causing disease. This provides protection if the person is later exposed to any of these bacteria. The primary indication is prevention of these infections in infants, children, adolescents, adults, pregnant women (to protect newborns), healthcare workers, or anyone at risk of exposure[5][6][8]. Multiple formulations exist for different age groups: DTaP for children under 7 years old; Tdap as a booster for older children (>7 years), adolescents, adults, or pregnant women[1][3][4].
- Brand names
- DAPTACEL
- Other names
- DTaPTdapdiphtheria, tetanus, and acellular pertussis vaccinediphtheria-tetanus-acellular pertussis vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria and tetanus toxoids and acellular pertussis adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids and acellular pertussis adsorbed.